A Double-Blind, Randomised, Placebo-Controlled Study to Evaluate Three Dose Regimens of Ragweed-SPIRE in Ragweed Allergic Subjects Following Challenge With Ragweed Allergen in an Environmental Exposure Chamber
Phase of Trial: Phase II
Latest Information Update: 22 Apr 2015
At a glance
- Drugs Ragweed SPIRE (Primary)
- Indications Allergic rhinoconjunctivitis; Ragweed pollen hypersensitivity
- Focus Therapeutic Use
- Sponsors Circassia
- 19 Mar 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 06 Nov 2014 Status changed from completed to active, no longer recruiting as reported by ClinicalTrials.gov
- 24 Oct 2014 According to the ClinicalTrials.gov record, status changed from active, no longer recruiting to completed.